From Podium to Practice: Updates in HCV Treatment

[Guest guest]

From Podium to Practice: Updates in HCV Treatment

Capsule Summaries

Pilot Study Shows Robust Antiviral Activity With GS-9256 and Tegobuvir (GS-9190)–Based 4-Week Lead-in Regimens in Treatment-Naive Patients With Genotype 1 HCV After 12 Weeks of Telaprevir Treatment, PegIFN/RBV Can Be Shortened to 24 Weeks in HCV Genotype 1 Patients Achieving Extended RVR SPRINT-2: Boceprevir Plus PegIFN/RBV for 24 Weeks Improves SVR Rates vs PegIFN/RBV in Treatment-Naive Patients With Genotype 1 HCV

BMS-790052 and BMS-650032 Coadministration Associated With Undetectable HCV RNA After 12 Weeks of Therapy With or Without PegIFN/RBV in Genotype 1 HCV Null Responders ANA598 Improves HCV RNA Response to PegIFN/RBV in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection Danoprevir Added to Standard PegIFN/RBV for 12 Weeks Associated With Rapid and Potent Viral Suppression in Patients With Genotype 1 HCV Infection PROPEL: RG7128 Plus PegIFN alfa-2a/RBV Demonstrates High Rates of RVR and cEVR in Treatment-Naive Patients Infected With Genotype 1/4 HCV Vaniprevir (MK-7009) With Peginterferon alfa-2a Plus Ribavirin Produces Higher RVR Rates in Treatment-Naive Genotype 1 HCV Patients ADVANCE: Telaprevir Plus PegIFN/RBV Associated With Significant Increases in SVR in Treatment-Naive Patients With Genotype 1 HCV RESPOND-2: High SVR Rates With Boceprevir and PegIFN/RBV Combination Therapy in Patients With Genotype 1 HCV Failing Previous PegIFN/RBV MK-5172 Demonstrated Potent Antiviral Activity in Patients With Chronic Genotype 1 or 3 HCV Infection Modeling Study Results Support IL-28B Genotype Stratification in HCV Clinical Trials of PegIFN/RBV Plus Direct-Acting Antivirals Peginterferon Lambda Demonstrates Promising Early Virologic Response and Favorable Tolerability for the Treatment of HCV Infection Higher Early Virologic Response With Telaprevir Plus PegIFN/RBV vs PegIFN/RBV or Telaprevir Monotherapy but Similar Rates of SVR in Treatment-Naive Patients With Genotype 4 HCV

http://www.clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202010/Tracks/HCV%20Treatment.aspx